Sumeet Singh-Tan

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/d41fe610-497e-11ec-8149-d1681d4b2362.jpg

First Name

Sumeet

Last Name

Singh-Tan

NPI

1215318001

Faculty ID

16569

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

14316

Is Open Scheduling

Off

Mark Shlomovich

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/f00957b0-d372-11ed-b9ca-f36b2b5dc5fe.jpg

First Name

Mark

Last Name

Shlomovich

NPI

1790065910

Faculty ID

15549

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Areas

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

EMR ID

29419

Biography

<p>Mark Shlomovich, MD, is Director, Extracorporeal Liver Support and Director, Pediatric Critical Care Transport at Children&rsquo;s Hospital at Montefiore and Assistant Professor, Pediatrics at Montefiore-Einstein. Dr. Shlomovich&rsquo;s clinical focus is on the care of critically ill children with abdominal organ failure, transplantation and post-surgical care. He also focuses on the safe transportation of critically ill children.</p><p>In 2006, Dr. Shlomovich earned his Bachelor of Science in biology from Towson University. He then attended University of Connecticut School of Medicine earning his Doctor of Medicine in 2010. His postgraduate training began at SUNY Downstate Medical Center with a four-year pediatric residency, where he was Chief Pediatric Resident in his final year. He then came to Children's Hospital at Montefiore for a pediatric critical care fellowship, which he completed in 2017.</p><p>Dr. Shlomovich&rsquo;s research interests are in the use of artificial liver support technology, as well as the care of children in liver failure before and after transplantation. In addition, he investigates the safety and efficiency of the transportation of critically ill children. He has shared his research through peer-reviewed journals and abstracts, and is an ad hoc reviewer for BMC Nephrology.</p><p>Dr. Shlomovich is board certified in general pediatrics and pediatric critical care medicine. He is a member of the Society of Critical Care Medicine and the American Academy of Pediatrics.</p>

Is Open Scheduling

Off

Adarsha Selvachandran

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/b851f490-5fb9-11ec-9773-d197dc92a0d8.jpg

First Name

Adarsha

Last Name

Selvachandran

NPI

1134578248

Faculty ID

16723

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

87590

Is Open Scheduling

Off

Scott J. Schafler

https://assets.montefioreeinstein.org/profiles/images/Scott-Schafler.jpg

First Name

Scott

Last Name

Schafler

NPI

1417219585

Faculty ID

16440

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

55639

Is Open Scheduling

Off

Alexander I. Sankin

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/6a135040-3a87-11ed-8158-59ecbd24247c.jpg

First Name

Alexander

Last Name

Sankin

NPI

1982866570

Faculty ID

14891

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Sankin is an academic surgeon in the Department of Urology, at Montefiore Medical Center with a clinical focus on surgical approaches to the management of urologic malignancies of the upper urinary tract and bladder. His academic focus is divided between clinical and translational research studying emerging treatments and techniques central to the surgical care of patients with urologic cancers.&nbsp;</p>
<p>Dr. Sankin is the site-Principal Investigator for multiple clinical trials studying novel therapeutics for patients with bladder cancer who wish to avoid radical cystectomy. As an active member of multiple clinical trial consortiums including Eastern Cooperative Oncology Group and the Society of Urologic Oncology Clinical Trials Consortium, Dr. Sankin speardeaded the development of a bladder cancer clinical trials program at Einstein.&nbsp;</p>
<p>His translational research focuses on characterizing the tumor immune microenvironment of bladder tumors and the role of novel checkpoint molecules as relevant therpeutic targets. &nbsp;</p>
<p>&nbsp;</p>

Research Areas

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Sankin current research program focuses on the translational application of immune-oncology to the treatment of urologic cancer.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Sankin's&nbsp;clinical specialty is surgical approaches to treating urological malignancies, including prostate, testicular, renal and bladder cancer.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Building on his clinical focus, Dr. Sankin&rsquo;s research centers on bladder-preserving treatment options in patients with high-risk bladder cancer and the development of new immunotherapies for bladder cancer.&nbsp;<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

Selected Publications

<p align="left">Clark TW,&nbsp;Sankin A, Becske T, Nelson PK, Fox M.&nbsp;&nbsp;Stent-assisted Gugliemi detachable coil repair of wide-necked renal artery aneurysm using 3-D angiography.&nbsp;&nbsp;Vasc Endovascular Surg 2008 Jan; 41(6):528-32</p>
<p align="left">Tareen B,&nbsp;Sankin A, Godoy G, Temkin S, Lepor H, Taneja SS.&nbsp;Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort<em>.</em>&nbsp;Urology.&nbsp;&nbsp;2009 Feb;73(2):351-4</p>
<p align="left">Tareen B, Godoy G,&nbsp;Sankin A, Temkin S, Lepor H, Taneja SS.&nbsp;&nbsp;Laterality alone should not drive selection of candidates for hemi-ablative focal therapy.&nbsp;J Urol.&nbsp;&nbsp;2009 Mar;181(3):1082-9</p>
<p align="left">Tareen B, Godoy G,&nbsp;Sankin A, Temkin S, Lepor H, Taneja SS.&nbsp;&nbsp;Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?&nbsp;&nbsp;BJU Int. 2009 Jul;104(2):195-9</p>
<p align="left">Marien T,&nbsp;Sankin A, Lepor H.&nbsp;&nbsp;Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy.&nbsp;&nbsp;J Urol.&nbsp;&nbsp;2009 Apr;181(4):1817-22</p>
<p align="left">Sankin A, Tareen B, Lepor H.&nbsp;&nbsp;Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy.&nbsp;&nbsp;Prostate Cancer Prostatic Dis.&nbsp;&nbsp;2009;12(2):204-8</p>
<p align="left">Mufarrij P,&nbsp;Sankin A, Godoy G, Lepor H.&nbsp;Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy.&nbsp;&nbsp;Urology.&nbsp;&nbsp;2010 Sep;76(3):689-92</p>
<p align="left">Sankin A, Cohen J, Wang H, Macchia RJ, Karanikolas N.&nbsp;&nbsp;Rate of renal cell carcinoma subtypes in different races.&nbsp;&nbsp;Int Braz J Urol.&nbsp;&nbsp;2011 Feb;37(1):29-32</p>
<p align="left">Sankin A, Sfakianos J, Schiff J, Sjoberg D, Coleman J.&nbsp;Assessing renal function following partial nephrectomy using renal nuclear scintigraphy and eGFR.&nbsp;&nbsp;Urology.&nbsp;&nbsp;2012 Aug;80(2):343-6</p>
<p align="left">Ghavamian R, Hakimi AA, Williams SK, Kim PH, Chen L, Sfakianos JP, Keren-Paz GE,&nbsp;Sankin A,&nbsp;Ginzburg N, Coleman JA.&nbsp;&nbsp;Factors affecting proportional glomerular filtration rate following minimally invasive partial nephrectomy.&nbsp;&nbsp;J Endourology&nbsp;&nbsp;2013 Nov;27(11):1371-5</p>
<p align="left">Sankin A, Hakimi AA, Mikkilineni N, Ostrovnaya I, Silk MT, Liang Y, Mano R, Chevinsky M, Motzer RJ, Solomon SB, Cheng EH, Durack JC, Coleman JA, Russo P, Hsieh JJ.&nbsp;&nbsp;The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling.&nbsp;&nbsp;Cancer Medicine 2014 Dec;3(6):1485-92</p>
<p align="left">Mano R, Vertosick E,&nbsp;Sankin A,&nbsp;Chevinsky M, Larish Y, Jakubowski CD, Hotker AM, Sjoberg D, Akin O, Russo P.&nbsp;&nbsp;The clinical significance of indeterminate pulmonary nodules in patients with renal cell carcinoma.&nbsp;&nbsp;J Urol 2014 Mar;193(3):776-82</p>
<p align="left">Chevinsky M, Imnadze M,&nbsp;Sankin A, Winer A, Mano R, Jakubowski C, Mashni J, Sjoberg DD, Chen YB, Tickoo SK, Reuter VE, Hakimi AA, Russo P.&nbsp;Pathologic stage T3a significantly increases disease recurrence across all tumor sizes in renal cell carcinoma.&nbsp;J Urol 2015 Aug;194(2):310-5</p>
<p align="left">Hakimi AA, Tickoo S, Jacobsen A, Sarungbam J, Sfakianos J, Sato Y, Morikawa T, Kume H, Fukayama M, Homma Y, Chen YB,&nbsp;Sankin A,&nbsp;Mano R, Coleman JA, Russo P, Ogawa S, Sander C, Hsieh JJ, Reuter VE.&nbsp;TCEB1-mutated renal cell carcinoma: a distinct genomic and morphologic subtype.&nbsp;&nbsp;Mod Pathol 2015 June;28(6):845-53</p>
<p align="left">Sankin A,&nbsp;Hakimi AA, Hsieh JJ, Molina AM.&nbsp;&nbsp;Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies.&nbsp;&nbsp;Front Oncol 2015 Apr 8;5:67</p>
<p align="left">Hakimi AA, Ostrovnaya I, Jacobsen A, Susztak K, Coleman JA, Russo P, Winer AG, Mano R,&nbsp;Sankin A, Motzer RJ, Voss MH, Offit K, Purdue M, Pomerantz M, Freedman M, Choueiri TK, Hsieh JJ, Klein RJ.&nbsp;&nbsp;Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell&nbsp;carcinoma.&nbsp;&nbsp;Cancer 2016 Feb 1;122(3):402-10</p>
<p align="left">Sankin A. Discovering biomarkers within the genomic landscape of renal cell carcinoma.&nbsp;&nbsp;J Kidney 2016 Feb 2(1)&nbsp;</p>
<p align="left">Sankin A, Tin A, Mano R, Chevinsky M, Jakubowski C, Cha E, Yee A, Friedman F, Sjoberg D, Ehdaie B, Coleman J.&nbsp;&nbsp;Impact of ureteroscopy prior to nephroureterectomy for upper tract urothelial carcinoma on oncologic outcomes.&nbsp;&nbsp;Urology 2016 Aug; 94:148-53</p>
<p align="left">Mano R, Hakimi AA,&nbsp;Sankin AI,&nbsp;Sternberg IA, Chevinsky MS, Russo P.&nbsp;&nbsp;Surgical treatment of tumors involving kidneys with fusion anomalies &ndash; a contemporary series.&nbsp;&nbsp;Urology 2016 Aug; 98:97-102</p>
<p align="left">Zhou TC,&nbsp;Sankin A,&nbsp;Porcelli SA, Perlin DS, Schoenberg MP, Zang XX.&nbsp;&nbsp;A review of the PD-1/PD-L1 checkpoint in bladder cancer: from mediator of immune escape, to target for treatment.&nbsp;&nbsp;Urol Oncol 2017 Jan;35(1):14-20&nbsp;</p>
<p align="left">Winer AG, Vertosick EA, Ghanaat M, Corradi RB, Carlsson S, Sjoberg DD,&nbsp;Sankin AI,&nbsp;Sfakianos JP, Cha EK, Dalbagni G, Coleman JA.&nbsp;Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma.&nbsp;&nbsp;Urol Oncol 2017 April;35(4):151</p>
<p align="left">Sankin&nbsp;A,&nbsp;Narasimhulu&nbsp;D, John P,&nbsp;Gartrell&nbsp;B, Schoenberg M, Zang XX.&nbsp; The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: what lies beneath the tip of the iceberg, PD-L1.&nbsp;&nbsp;Urol&nbsp;Onc&nbsp;2017 (Epub ahead of print)</p>
<p align="left">Milbar N, Kates M, Chappidi MR, Pederzoli F, Yoshida T,&nbsp;Sankin A,&nbsp;Pierorazio PM, Schoenberg MP, Bivalacqua TJ. Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer.&nbsp;&nbsp;Bladder Cancer 2017 Oct 27;3(4):293-303</p>
<p align="left">Daneshmand S, Patel s, Lotan Y, Pohar K, Trabulsi E, Woods M, Downs T, Huang W, Jones J, O&rsquo;Donnell M, Bivalacqua T, DeCastro J, Steinberg G, Kamat A, Resnick M, Konety B, Schoenberg M, Jones JS,&nbsp;Flexible Blue Light Study Group Collaborators.&nbsp;Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study.&nbsp;&nbsp;J Urol 2018 May;199(5):1158-65</p>
<p align="left">Fridman D, Abeshouse M,&nbsp;Sankin A.&nbsp;Paraurethral Leiomyoma as an Incidental Finding in a Patient with Fibroid Uterus. Case Rep Obstet Gynecol 2018 Feb 7;2018</p>
<p align="left">Adrianzen Hererra DA, Goldberg-Stein S,&nbsp;Sankin A, Sarungbam J, Sharma J, Gartrell BA. Synchronous Bone Metastasis From Multiple Myeloma and Prostate Adenocarcinoma as Initial Presentation of Coexistent Malignancies. Front Oncol, 2018 Apr 30;8:137</p>
<p align="left">Berstein A, Fram EB,&nbsp;Sankin A, Kovac E, Srivastava A, DiVito J, Stern JM. A Comparison of Perinephric Fat Surface Area and Mayo Adhesive Probability Score in Predicting Malignancy in T1 Renal Masses.&nbsp;&nbsp;Urol Onc 2018 Nov; 36(11):499</p>
<p align="left">Sun Y, Reuter VE, Magi-Galluzzi C,&nbsp;Sankin A,&nbsp;Epstein JI.&nbsp;Granular Cell Tumor of the Bladder: A Report of Six Cases.&nbsp;&nbsp;Urology 2018 Nov; 121:203&nbsp;</p>
<p align="left">Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, Heidenreich A, Messing EM, Royce TJ,&nbsp;Sankin A,&nbsp;Schoenberg MP, Shipley WU, Villers A, Efstathiou J, Bellmunt J, Stenzl A.&nbsp;&nbsp;Recommendations From Joint SIU-ICUD Consultation On Bladder Cancer: Muscle-Invasive Presumably Regional Tumor.&nbsp;&nbsp;World J Urol 2019, Jan;37(1): 61-83</p>
<p align="left">Chand D, Dhawan D,&nbsp;Sankin A, Ren X, Lin J, Schoenberg M, Knapp DW, Zang X. Immune checkpoint B7x (B7-H4/B7S1/VtCN1) is overexpressed in spontaneous canine bladder cancer: the first report and its implications in a preclinical model. Bladder Cancer 2019, Jan 31;5(1)63-71</p>
<p align="left">Bernstein A, Barry E, Fram EB,&nbsp;Sankin A,&nbsp;Kovac E, Stern JM.&nbsp;Does Glomerular Filtration Rate at Discharge After Partial Nephrectomy Predict Long-Term Glomwerular Filtration Rate Stability?. J Endourol 2019, Jun;33(6):488-491</p>
<p align="left">Lotan Y, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat A, Konety B, Malmstrom PU, McKiernan J, O&rsquo;Donnell M, Patel S, Pohar K, Resnick M,&nbsp;Sankin A,&nbsp;Smith A, Steinberg G, Trabulsi E, Woods M, Daneshmand S.&nbsp;&nbsp;Blue light flexible cystoscopy with hexaminolevulinate in non-muscle invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA &ndash; update 2018. Nat Rev Urol 2019, Jun;16(6):377-386</p>
<p align="left">Sankin A,&nbsp;Chand D, Schoenberg M, Zang X.&nbsp;&nbsp;Human urothelial bladder cancer generates a clonal immune response: the results of T-cell receptor sequencing.&nbsp;&nbsp;Urol Oncol 2019, May 15 (epub ahead of print).</p>
<p align="left">Wang H, Kaur G,&nbsp;Sankin A,&nbsp;Chen F, Guan F, Zang X.&nbsp;Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies.&nbsp;&nbsp;J Hematol Oncol 2019, Jun 11;12(1):59</p>
<p align="left">Daniels MJ, Barry E, Schoenberg M, Lamm DL, Bivalacqua TJ,&nbsp;Sankin A, Kates M.&nbsp;&nbsp;Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer. Urol Oncol 2019, Jun 26 (epub ahead of print)</p>
<p align="left">Daniels MJ, Barry E, Milbar N, Schoenberg M, Bivalacqua TJ,&nbsp;Sankin A, Kates M. An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle invasive bladder cancer.&nbsp;&nbsp;Urol Oncol 2019, Aug 28 (epub ahead of print)</p>
<p align="left">Khaki AR, Li A, Diamantopoulos LN, Bilen MA, Santos V, Esther J, Morales-Barrera R, Devitt M, Nelson A, Holmes CJ, Shreck E, Assi H, Gartrell BA, Sankin A,&nbsp;Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Baratam P, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P.&nbsp;&nbsp;Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors.&nbsp;&nbsp;Cancer 2019, Dec 12 (epub ahead of print)</p>

EMR ID

78143

Biography

<p>Alexander I. Sankin, MD, is Associate Professor, Urology at Montefiore Einstein. His clinical specialty is surgical approaches to treating urological malignancies, including prostate, testicular, renal and bladder cancer.</p><p>After earning his Master of Science from the University of Pennsylvania in 2004, Dr. Sankin earned his Doctor of Medicine from New York University in 2008 and completed his residency in surgery and urology at the State University of New York Downstate in 2013. He then completed a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center in 2015.</p><p>Building on his clinical focus, Dr. Sankin&rsquo;s research centers on bladder-preserving treatment options in patients with high-risk bladder cancer and the development of new immunotherapies for bladder cancer. He is the site-principal investigator for multiple clinical trials studying novel therapeutics for patients with bladder cancer who wish to avoid radical cystectomy. As an active member of multiple clinical trial consortiums, including Eastern Cooperative Oncology Group and the Society of Urologic Oncology Clinical Trials Consortium, Dr. Sankin spearheaded the development of a bladder cancer clinical trials program at Einstein. His translational research focuses on characterizing the tumor immune microenvironment of bladder tumors and the role of novel checkpoint molecules as relevant therapeutic targets. His work has been published in numerous peer-reviewed journals.</p><p>Dr. Sankin is board certified and a member of the American Urological Association and the Society of Urologic Oncology.</p>

Is Open Scheduling

Off

Shawn K. Samuel

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Shawn

Last Name

Samuel

NPI

1649366204

Faculty ID

11069

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

8928

Is Open Scheduling

Off

Evelyn M. Rondinel

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/31d12950-3cae-11ec-9e23-c5d5559390c7.jpg

First Name

Evelyn

Last Name

Rondinel

NPI

1821138702

Faculty ID

18003

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4488

Is Open Scheduling

Off

Jessica Rieder

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/fed42100-891b-11ec-b5d6-3f90a6bc79f5.jpg

First Name

Jessica

Last Name

Rieder

NPI

1053496414

Faculty ID

1063

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><span style="color: black; font-family: 'Verdana',sans-serif; font-size: 10.5pt;">Jessica Rieder, MD, MS, a board-certified specialist in adolescent medicine, is Associate Professor of Pediatrics at the Albert Einstein College of Medicine of Yeshiva University. She earned her bachelor&rsquo;s degree in biochemistry and M.D. degree with honors in research from the University of Alberta. She completed her clinical training including pediatric residency, chief residency, and adolescent medicine fellowship at the Children&rsquo;s Hospital at Montefiore.&nbsp; She joined the pediatric faculty at Einstein/Montefiore upon completion of her fellowship and subsequently earned a master&rsquo;s degree in clinical research from the Albert Einstein College of Medicine of Yeshiva University.</span></p>
<p style="margin: 0in; text-align: justify;"><span style="color: black; font-family: 'Verdana',sans-serif; font-size: 10.5pt;">Dr. Rieder h</span><span style="font-family: 'Verdana',sans-serif; font-size: 10.5pt; mso-bidi-font-family: Arial;">as been engaged in </span><span style="font-family: 'Verdana',sans-serif; font-size: 10.5pt; mso-fareast-font-family: Arial; mso-bidi-font-family: Arial;">action-oriented, policy-relevant research which has been informed </span><span style="font-family: 'Verdana',sans-serif; font-size: 10.5pt; mso-bidi-font-family: Arial;">by the weight management efforts that have been the focus of her career for over a decade. She is the founder and director of the Bronx Nutrition and Fitness Initiative for Teens (B&rsquo;N Fit), </span><span style="color: black; font-family: 'Verdana',sans-serif; font-size: 10.5pt;">a joint venture between the Children&rsquo;s Hospital at Montefiore and the Mosholu Montefiore Community Center (MMCC). She has had extensive experience with the </span><span style="font-family: 'Verdana',sans-serif; font-size: 10.5pt; mso-bidi-font-family: Arial;">development, administration, and evaluation of </span><span style="color: black; font-family: 'Verdana',sans-serif; font-size: 10.5pt;">B&rsquo;N Fit, which </span><span style="font-family: 'Verdana',sans-serif; font-size: 10.5pt; mso-bidi-font-family: Arial;">offers comprehensive weight management programming for inner-city youth, ages 12-21 years</span><span style="color: black; font-family: 'Verdana',sans-serif; font-size: 10.5pt;">. </span><span style="font-family: 'Verdana',sans-serif; font-size: 10.5pt; mso-bidi-font-family: Arial;">She has an interest in the clinical and behavioral management of adolescent obesity as well as clinical care access issues that prevent impoverished adolescents from accessing weight management services. A decade-long partnership with MMCC and more recently with the Montefiore School Health Program has resulted in youth-focused school-based afterschool programming that aims to <span style="mso-spacerun: yes;">&nbsp;</span>more effectively support a population characterized by significant psychosocial stressors, economic crisis, developing autonomy and noncompliance.<span style="mso-spacerun: yes;">&nbsp; </span>Dr. Rieder continues to enjoy partnering with clinical, research, community, advocacy, administrative, technology, and educational collaborators to design initiatives that engage and support youth and families interested in lifestyle programming that promotes long-term health and prevents illness. <span style="mso-bidi-font-weight: bold;"><span style="mso-spacerun: yes;">&nbsp;</span></span></span></p>
<p>&nbsp;</p>
<p style="margin: 0in;"><span style="font-family: Arial; font-size: medium;">&nbsp;</span></p>
<p><span style="font-family: Times New Roman;"> <br /></span></p>

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Rieder, is a board-certified specialist in adolescent medicine and the founder and director of the Bronx Nutrition and Fitness Initiative for Teens (B’N Fit) weight management program. Dr. Rieder’s academic interests include adolescent obesity and its complications, in particular, ovarian hyperandrogenism or polycystic ovary syndrome.</p>

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

Adolescent medicine, adolescent gynecology, adolescent obesity

Research Focus

Adolescent obesity, adolescent gynecology with research interests in weight management program evaluations and polycystic ovarian syndrome

Elsevier Profile

Selected Publications

<p>&nbsp;</p>
<p style="margin: 0in; text-align: justify;"><span style="font-family: Arial;"><span style="font-size: medium;"><strong style="mso-bidi-font-weight: normal;"><span style="mso-bidi-font-family: Arial;">Link to Complete List of Published Work in My Bibliography. </span></strong></span><span style="background: white; color: black; font-size: 8pt;">&nbsp;</span></span></p>
<p>&nbsp;</p>
<p style="margin: 0in; text-align: justify;"><a href="http://www.ncbi.nlm.nih.gov/sites/myncbi/1rcYFranZwvAc/bibliography/487… style="background: white; padding: 0in; border: 1pt windowtext; color: #2f4a8b; mso-bidi-font-size: 8.0pt; mso-bidi-font-family: Arial; mso-border-alt: none windowtext 0in;"><span style="font-family: Arial; font-size: medium;">http://www.ncbi.nlm.nih.gov/sites/myncbi/1rcYFranZwvAc/bibliography/487…;
<p>&nbsp;</p>
<p style="margin: 0in; text-align: justify;"><span style="background: white; padding: 0in; border: 1pt windowtext; color: #2f4a8b; mso-bidi-font-size: 8.0pt; mso-bidi-font-family: Arial; mso-border-alt: none windowtext 0in;"><u><span style="font-family: Arial; font-size: medium;">&nbsp;</span></u></span></p>
<p>&nbsp;</p>

EMR ID

4076

Biography

<p>Jessica Rieder, MD, a board-certified specialist in adolescent medicine, is Associate Clinical Professor of Pediatrics at Albert Einstein College of Medicine. She is founder and Director of the Bronx Nutrition and Fitness Initiative for Teens (B&rsquo;N Fit) weight management program, a joint venture between The Children&rsquo;s Hospital at Montefiore and the Mosholu Montefiore Community Center.</p><p>Dr. Rieder earned her bachelor&rsquo;s degree in biochemistry from the University of Alberta in 1990 and her MD degree with honors in research from the same university in 1994. She completed her clinical training, including pediatric residency, chief residency and adolescent medicine fellowship, at The Children&rsquo;s Hospital at Montefiore. She joined the pediatric faculty at Einstein and Montefiore upon completion of her fellowship in 2001. In 2003 Dr. Rieder earned a master&rsquo;s degree in clinical research from Albert Einstein College of Medicine.</p><p>Dr. Rieder&rsquo;s academic interests include adolescent obesity and its complications, in particular, ovarian hyperandrogenism or polycystic ovary syndrome. As Director of the B&rsquo;N Fit Program, she oversees a clinical and research team of physicians, a nutritionist, a social worker, and administrative and support staff. Dr. Rieder is funded through the Department of Health and Human Services Health Resources and Services Administration, the New York State Health Foundation and private foundations to conduct short- and long-term effectiveness evaluations of the B&rsquo;N Fit program.</p>

Is Open Scheduling

Off

Kimberly J. Reidy

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/3968bb50-3ab5-11ed-8158-59ecbd24247c.jpg

First Name

Kimberly

Last Name

Reidy

NPI

1760652556

Faculty ID

10200

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Languages

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

EMR ID

4390

Biography

<p>Kimberly J. Reidy, MD, is Chief, Division of Pediatric Nephrology and Associate Professor at Children&rsquo;s Hospital at Montefiore (CHAM) and Montefiore Einstein. Her clinical focus is on the treatment of hypertension and childhood-onset kidney disease. She has particular interest in nephrotic syndrome and glomerular diseases, congenital abnormalities of the kidney and urinary tract, and genetic kidney diseases.</p><p>After earning her Bachelor of Arts in chemistry at Princeton University in 1997, Dr. Reidy attended Albert Einstein College of Medicine, earning her Doctor of Medicine in 2002. Her postdoctoral training began with a pediatric internship and residency at Children&rsquo;s Hospital of New York, NewYork-Presbyterian from 2002 to 2005. She then pursued a three-year National Institutes of Health (NIH) supported fellowship in pediatric nephrology at CHAM, completing it in 2008.</p><p>Dr. Reidy&rsquo;s clinical research focuses on children with glomerular and chronic kidney disease, including NIH funded Nephrotic Syndrome Study Network (NEPTUNE) and Cure Glomerulonephropathy (CureGN) studies of children with nephrotic syndrome. Her translational research focuses on the effect of APOL1 risk variants on preeclampsia and perinatal outcomes. Her bench research focuses on effects of developmental genes on kidney repair and fibrosis after injury. She has shared her work through many peer-reviewed journals, invited presentations, book chapters and abstracts. Dr. Reidy is also an ad hoc reviewer for many journals including <em>Pediatric Nephrology, Kidney International and the Journal of the American Society of Nephrology</em>.</p><p>Dr. Reidy is board-certified in pediatrics and pediatric nephrology. She is an active member of several professional organizations including the American Society of Pediatric Nephrology, the American Academy of Pediatrics (AAP) and the Neonatal Kidney Collaborative. She currently serves on the Executive Committee of the Section of Nephrology for the AAP. From 2016 through 2021, she has been listed among Castle Connolly Top Doctors: New York Metro Area. In 2021, she was elected to membership in the Leo M. Davidoff Society, recognizing her long-term commitment to excellence in teaching medical students.</p>

Is Open Scheduling

Off

Samuel J. Rednor

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Samuel

Last Name

Rednor

NPI

1265775167

Faculty ID

16224

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Nephrology and Critical Care.

Research Focus

Dr. Rednor&rsquo;s research focus is in acute kidney injury (AKI), cardiac arrest, and intubation.&nbsp;

Elsevier Profile

EMR ID

87716

Biography

<p>Samuel J. Rednor, DO, is Director of Wellness, Critical Care and Assistant Professor, Medicine at Montefiore Einstein. His clinical focus is nephrology and critical care.</p><p>After earning his Doctor of Osteopathic Medicine at Lake Erie College of Osteopathic Medicine in 2013, Dr. Rednor completed his residency in internal medicine at Southampton Hospital in 2016, where he was Chief Resident for one year. He then completed his renal fellowship at Montefiore in 2018, where he was Chief Renal Fellow during his last year. Dr. Rednor went on to complete an additional fellowship at Montefiore in critical care, which he completed in 2019.</p><p>Dr. Rednor&rsquo;s research focus is in acute kidney injury (AKI), cardiac arrest, and intubation. His work has been published in peer-reviewed journals and he has given multiple lectures and presentations.</p><p>Dr. Rednor is board certified in Internal Medicine, Nephrology and Critical Care Medicine by the American Osteopathic Board of Internal Medicine. He is a member of the American Society of Nephrology (ASN), the American Osteopathic Association (AOA), the Society of Critical Care Medicine (SCCM) and the American College of Chest Physicians (CHEST). In 2018, Dr. Rednor won the Sharon R. Silbiger Teaching Award for excellence in teaching and in recognition as Outstanding Fellow of the Year from Einstein.</p>

Is Open Scheduling

Off